Market Size (2021)
$2.02B
Market Research ReportStandard
Apheresis Market
Apheresis Market Research Report: Size, Share, Trend Analysis By 44915 (1) and By 0.213 (0.236, 1) - Growth Outlook & Industry Forecast To 2021
Vertical: Healthcare
Vertical: Healthcare
Market Size (2021)
$2.02B
Projected (2021)
$2.02B
CAGR (2021–2021)
N/A
Key Players
10+
This report covers Apheresis Market with forecasts from 2021 to 2021. 10 key companies are profiled.
Apheresis Market is a key focus area for market intelligence and strategic research.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The increasing prevalence of chronic diseases, rising demand for plasma-derived therapies, and favorable reimbursement policies are fueling the growth of the US Apheresis Market. Additionally, high procedure costs, safety concerns in blood transfusions, and the recruitment of voluntary non-remunerated donors are restraining factors for the market. However, the increasing demand for platelet-rich plasma therapy and apheresis for leukemia and pediatric patients will provide growth opportunities for the market in the future.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
—
Historical Period
2021 – 2021
Forecast Period
2021 – 2021
Primary Interviews
—
Historical performance and future projections
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Michael Porter's Five Forces model is a framework to study the US Apheresis Market. Strategic business managers trying to gain an edge over competing firms in the US Apheresis Market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the US Apheresis Market have been broken down and analyzed.
PORTER'S FIVE FORCES ANALYSIs: US Apheresis Market
Threat of New Entrants
The threat of new entrants in the US apheresis market is relatively moderate to low due to several high barriers to entry. The apheresis market requires significant capital investment, advanced technological expertise, and compliance with stringent regulatory standards, such as FDA approvals for devices and treatments. Additionally, established companies in this market benefit from strong brand recognition, loyal customer bases, and established relationships with healthcare providers. Furthermore, the specialized nature of apheresis procedures, which involve the separation of blood components, requires skilled personnel and costly equipment, making it challenging for new entrants to compete effectively. Thus, while the growing demand for apheresis therapies may attract new players, the barriers limit their ability to quickly gain market share.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in the US apheresis market is moderate to high. This is because suppliers of essential raw materials, such as blood collection and separation equipment, consumables like apheresis kits, and specialized medical devices, play a critical role in the functioning of apheresis procedures. There are relatively few suppliers that provide high-quality, FDA-approved products that meet the necessary safety and regulatory standards. This limited supply, coupled with the advanced technological requirements of the apheresis process, gives suppliers significant leverage over pricing and availability. However, the presence of a few large suppliers and the ability of hospitals and clinics to negotiate for bulk purchasing can somewhat reduce this power.
Threat of Substitutes
The threat of substitutes in the US apheresis market is moderate, as there are alternative medical treatments for certain conditions treated by apheresis, such as blood transfusions, drug therapies, or other methods like plasmapheresis or photopheresis. While apheresis is highly effective for conditions such as autoimmune diseases, neurological disorders, and blood cancers, patients may turn to alternative therapies depending on cost, availability, or the potential side effects of apheresis treatments. However, due to the specialized nature and efficacy of apheresis in certain medical conditions, the threat from substitutes is somewhat limited. Still, technological advancements in other treatment modalities could increase competition over time.
Bargaining Power of Buyers
The bargaining power of buyers in the US apheresis market is generally moderate. Buyers in this market are healthcare providers, including hospitals, clinics, and specialized treatment centers, which procure apheresis equipment and services. While the apheresis market is relatively concentrated, with a few dominant players providing most of the technology, healthcare buyers still have some leverage, particularly in negotiating pricing, as they typically purchase in bulk and have alternatives for certain treatments. However, due to the specialized and highly regulated nature of the equipment and treatments, buyers are limited in their options. Furthermore, the increasing demand for apheresis, driven by the growing prevalence of conditions requiring this therapy, somewhat diminishes the bargaining power of individual buyers.
Intensity of Rivalry
The intensity of rivalry in the US apheresis market is high, driven by the presence of several well-established players and the growing demand for apheresis-based therapies. Companies compete on factors such as technological innovation, the efficacy of treatments, pricing, and customer service. Additionally, the market is characterized by constant innovation, with firms striving to develop more efficient, less invasive, and safer apheresis procedures and equipment. The high cost of research and development, along with regulatory hurdles, intensifies competition as companies aim to differentiate themselves and capture larger market shares. As more healthcare providers incorporate apheresis into their treatment offerings, the level of rivalry is expected to remain high, with firms competing for both market share and reputation within the medical community.
Impact of covid-19 on the US Apheresis Market
The impact of COVID-19 on the US apheresis market was profound and multifaceted, presenting both significant challenges and new opportunities for growth. At the onset of the pandemic, the apheresis market faced substantial disruptions, primarily due to the diversion of healthcare resources towards managing the COVID-19 crisis. Hospitals and healthcare facilities were forced to prioritize COVID-19 patients, leading to the postponement or cancellation of elective medical procedures, including apheresis treatments. This resulted in a temporary but sharp decline in apheresis procedures, particularly for conditions like autoimmune diseases, neurological disorders, and blood cancers, which typically require regular apheresis treatments. Patients who depended on these life-saving therapies experienced delays, exacerbating health conditions for some and highlighting the critical role that apheresis plays in managing chronic and severe diseases.
In addition to the procedural delays, the apheresis market was significantly impacted by disruptions in the supply chain. The global supply chain for medical equipment and consumables, including blood separation kits, filters, and other specialized devices required for apheresis, was severely strained. Manufacturing delays, restrictions on the movement of goods, and reduced production capacities led to shortages of essential supplies, further hindering the ability of healthcare providers to perform apheresis treatments. This situation was exacerbated by the heightened demand for personal protective equipment (PPE) and other resources to fight COVID-19, diverting attention and resources away from the apheresis market.
However, while the pandemic initially disrupted the apheresis market, it also revealed its critical importance in addressing severe COVID-19 complications. As healthcare professionals learned more about the disease, apheresis therapies, particularly plasmapheresis and leukapheresis, emerged as important tools in treating patients with severe COVID-19 symptoms, such as cytokine storms, a hyper-inflammatory response that can cause severe organ damage. Apheresis was also recognized for its role in the collection of convalescent plasma, which was used to treat critically ill COVID-19 patients. The increased awareness of apheresis potential in the treatment of COVID-19-related complications led to a surge in demand for these therapies, partially offsetting the decline in other apheresis treatments.
In response to the pandemic, the apheresis market witnessed several key innovations and adaptations that contributed to its recovery and long-term growth. Healthcare systems embraced telemedicine and remote patient monitoring, which allowed for greater continuity of care and minimized patient exposure to COVID-19. The market also saw a renewed emphasis on blood donation, plasma collection, and the establishment of new centers dedicated to COVID-19 convalescent plasma collection. These efforts not only helped meet the increased demand for blood and plasma products but also underscored the long-term value of apheresis in managing public health crises.
See plans for professionals or small and medium businesses.
Analytical insights on Apheresis Market covering market dynamics, competitive landscape, and strategic outlook.
Apheresis Market represents a significant market opportunity with multiple growth drivers across regions and segments.
Introduction
The increasing prevalence of chronic diseases, rising demand for plasma-derived therapies, and favorable reimbursement policies are fueling the growth of the US Apheresis Market. Additionally, high procedure costs, safety concerns in blood transfusions, and the recruitment of voluntary non-remunerated donors are restraining factors for the market. However, the increasing demand for platelet-rich plasma therapy and apheresis for leukemia and pediatric patients will provide growth opportunities for the market in the future.
Increasing Prevalence of Chronic Diseases
The growing incidence of chronic diseases such as cardiovascular diseases, kidney disorders, autoimmune diseases, and diabetes in the United States is significantly driving the demand for apheresis services. Chronic diseases are not only becoming more common but also more complex, leading to an increased need for specialized treatments. For instance, according to a 2022 report from the CDC, approximately 805,000 people in the United States suffer from a heart attack each year. CAD is a major risk factor for heart attacks, highlighting the significant impact of heart-related conditions on the U.S. population. As per CDC 2022, about 5% of adults aged 20 and older (roughly 1 in 20 people) are affected by coronary artery disease (CAD), a condition where the arteries that supply blood to the heart become narrowed or blocked. According to the American Kidney Fund, Inc., there were 6,418 living donor transplants performed in the U.S. last year. Apheresis, particularly therapeutic apheresis, has emerged as an essential tool in managing these conditions. This procedure works by selectively removing certain components of blood—such as harmful antibodies, excess lipids, or cholesterol—that contribute to the progression of these diseases.
For example, in autoimmune diseases like lupus or myasthenia gravis, apheresis helps remove pathogenic antibodies that attack healthy tissues, while in cardiovascular conditions, it can reduce elevated LDL cholesterol levels (a key contributor to plaque buildup) in patients unresponsive to statins. By targeting specific elements in the blood, apheresis offers a highly effective and precise treatment that is often more tailored than traditional medications.
As the prevalence of chronic diseases continues to rise, especially among the aging population, the demand for apheresis services has surged. Older individuals are particularly susceptible to these long-term illnesses, as their immune systems weaken and the body’s ability to regulate processes diminishes with age. Furthermore, the increase in patients seeking personalized and less invasive treatments has led healthcare providers to adopt apheresis more frequently, making it an integral part of modern disease management. Thus, the growing burden of chronic diseases, especially among the aging population, is not only driving demand but also shaping the future growth of the apheresis services market.
Rising Demand for Plasma-Derived Therapies
Plasma-derived therapies, which utilize plasma collected from blood donations, have experienced significant growth in recent years, particularly in the treatment of conditions such as hemophilia, immune deficiencies, and certain neurological disorders like Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). These therapies, which include clotting factor concentrates for hemophilia or immunoglobulin therapies for immune disorders, are lifesaving and often require large amounts of plasma. Apheresis plays a critical role in these therapies by enabling the collection of plasma from healthy donors. The procedure allows for the selective removal of plasma components, ensuring that plasma is separated in a way that is optimal for these specialized treatments.
As the demand for plasma-derived therapies continues to rise, so does the need for a constant and reliable supply of plasma. With an aging population and an increasing prevalence of conditions like autoimmune diseases and rare blood disorders, the requirement for these therapies has surged. Consequently, the need for apheresis services, which facilitate the collection of plasma, has also escalated. These services are crucial for maintaining the supply of plasma, as apheresis allows for the efficient and targeted collection of plasma from healthy individuals, ensuring that the plasma is free from contaminants and of the highest quality. Additionally, apheresis can be used for specific plasma component separation, which is important in meeting the diverse therapeutic needs of patients.
Furthermore, advancements in plasma-derived therapies have expanded the range of conditions that can be treated with plasma products, creating even more demand for plasma donations and apheresis procedures. Healthcare systems across the U.S. are increasingly relying on apheresis to ensure a steady and safe supply of plasma, as the process is both effective and scalable. Innovations in the field, such as improved apheresis technology and better donor safety protocols, are making plasma collection more efficient and safer, helping to keep up with the growing need. As the demand for these therapies continues to increase, particularly in treating rare and chronic conditions, the U.S. apheresis services market is expected to continue expanding, driven by both technological advancements and the growing reliance on plasma-based treatments.
Favorable Reimbursement Policies
The expansion of reimbursement policies for apheresis procedures is a critical factor driving the growth of the U.S. apheresis services market. Historically, the high costs associated with apheresis procedures could limit access, particularly for patients who needed ongoing or specialized treatments. However, as reimbursement policies evolve and insurance providers increasingly recognize the clinical value and effectiveness of therapeutic apheresis, more patients are able to access these services. Insurance companies and government healthcare programs, including Medicare and Medicaid, have started to broaden their coverage of apheresis, which includes covering the costs of both the procedure itself and the necessary medical equipment, such as blood separation machines. This change in policy is particularly significant for individuals suffering from chronic diseases like autoimmune disorders, cardiovascular diseases, and kidney failure, who may require repeated apheresis treatments.
By covering therapeutic apheresis, insurance providers ensure that more patients can afford these life-saving treatments without bearing the full financial burden. This increased access has made apheresis a more viable treatment option for a wider segment of the population. For example, patients with conditions like myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), and hyperlipidemia, which may require regular apheresis procedures, are now able to undergo these treatments without the significant out-of-pocket expenses that might have previously limited their access. The growing trend of insurance companies and government programs covering these treatments encourages healthcare providers to incorporate apheresis more frequently into their treatment plans. As more providers offer this service as part of their standard care, the adoption of apheresis procedures is likely to continue rising.
Moreover, as the reimbursement environment becomes more supportive, healthcare providers are incentivized to improve their infrastructure and adopt advanced apheresis technologies. This, in turn, leads to higher efficiency, better patient outcomes, and a more streamlined delivery of services. It also encourages investment in research and development of newer apheresis techniques that may enhance therapeutic efficacy, making the procedure even more attractive for both providers and patients. The growing support for apheresis reimbursement, therefore, plays a crucial role in expanding the availability and adoption of these services, thus propelling the overall market growth. With reimbursement policies becoming more inclusive, the U.S. apheresis services market is poised for continued expansion, driven by improved accessibility, affordability, and the increasing recognition of the procedure's therapeutic value.
-RICH PLASMA THERAPY Platelet-rich plasma (PRP) therapy has garnered significant attention in recent years, particularly within the fields of orthopedics, dermatology, and sports medicine. The therapy involves using a patient’s own platelets, which are concentrated from their blood, to accelerate healing and tissue regeneration. However, the growing demand for PRP therapy has also led to an increased need for apheresis services, as this technique is often employed to collect platelets from healthy blood donors for PRP treatments. Apheresis allows for the efficient extraction of platelets, which are then used in PRP therapy to treat a variety of conditions such as musculoskeletal injuries, hair loss, and even skin rejuvenation. In orthopedics, PRP therapy is commonly used to treat tendon injuries, ligament sprains, and osteoarthritis by promoting tissue healing and reducing inflammation. In dermatology, it has gained popularity for its ability to stimulate hair growth in patients with androgenic alopecia (male or female pattern baldness) and improve the appearance of the skin by reducing wrinkles and promoting collagen production. As the clinical applications of PRP therapy expand and its regenerative properties are increasingly recognized, more healthcare providers are incorporating them into treatment regimens.
This shift is creating substantial demand for platelet collections, which in turn, is fueling the need for apheresis services. As PRP therapy continues to grow in popularity across these therapeutic areas, the apheresis services market stands to benefit greatly. The increase in demand for PRP treatments means that apheresis will play a crucial role in providing a sufficient supply of platelets, particularly for treatments involving patients who may not have access to their own platelets or for cases requiring higher volumes of platelets. This trend is expected to create significant growth opportunities within the apheresis services market, especially as the adoption of PRP therapy expands into other areas like regenerative medicine, dentistry, and even cosmetic surgery. Thus, the increasing use of PRP therapy across diverse medical specialties is expected to drive further demand for apheresis services, offering promising prospects for market expansion. The use of apheresis services in the treatment of leukemia and in pediatric patients represents a rapidly growing opportunity for the U.S. apheresis services market. Apheresis plays a crucial role in the management of leukemia, particularly in removing abnormal cells from the blood, which is essential for patients undergoing treatments like chemotherapy.
Additionally, apheresis is commonly utilized in stem cell transplantation, a standard procedure for pediatric leukemia patients. According to the American Cancer Society, leukemia is the most common cancer in children and teens, accounting for almost 1 in 3 cancers. However, childhood leukemia is still a rare disease overall. About 3 out of 4 leukemia cases among children and teens are acute lymphocytic leukemia (ALL), while most of the remaining cases are acute myeloid leukemia (AML). By collecting healthy stem cells from a donor or the patient’s own blood, apheresis supports the transplant process, helping to restore normal blood cell production after intensive treatments. In many pediatric leukemia cases, apheresis offers a vital step in ensuring the success of treatment and improving patient outcomes, making it an indispensable component of care. Pediatric patients, especially those diagnosed with blood-related cancers such as leukemia or immune system disorders like severe combined immunodeficiency (SCID), greatly benefit from apheresis procedures. These treatments allow for the collection of stem cells or the removal of harmful substances such as excess white blood cells or toxins, which can improve the overall health of the child and enhance their response to other therapies.
As the number of pediatric patients diagnosed with blood cancers and immune system disorders continues to rise, there is an increasing demand for specialized treatments like apheresis. This trend has led to an expansion in the use of apheresis services for pediatric care, particularly in personalized treatments tailored to each patient's specific condition.
High Procedure Costs
One of the key barriers hindering the growth of the U.S. apheresis services market is the high cost associated with these procedures. Apheresis requires specialized and often expensive equipment, such as blood separation machines, as well as trained medical personnel to perform the procedure effectively. These factors contribute to the overall expense, which can deter some patients and healthcare providers from choosing apheresis, especially when alternative treatments are available at lower costs. Additionally, the ongoing need for medical supplies, continuous patient monitoring, and follow-up care further compounds the financial burden. Despite the proven clinical benefits of apheresis for treating various conditions, the high costs associated with the procedure remain a significant challenge, limiting its wider adoption and restricting market growth.
Safety Concerns in Blood Transfusions
Safety concerns related to blood transfusions, which are often a component of the apheresis process, present a significant challenge to the growth of the U.S. apheresis services market. Although apheresis is generally considered a safe and effective treatment, the inherent risks of blood transfusions can deter both patients and healthcare providers from fully embracing the procedure. These risks include the potential for infections, allergic reactions, or other adverse effects that could occur during or after the apheresis procedure. In particular, the transmission of bloodborne pathogens such as HIV, hepatitis B and C, and other infectious diseases, remains a serious concern despite advancements in screening, sterilization, and blood safety protocols. For example, as per the National Institutes of Health (NIH) while the risk of HIV transmission via blood transfusion is now 1 in 1.5 million per unit transfused due to improved testing fears persist among patients.
For patients who require frequent or long-term apheresis treatments—such as those with autoimmune disorders, kidney failure, or hyperlipidemia—the cumulative risks associated with repeated blood transfusions may heighten concerns. A 2019 study in Transfusion found that 10-30% of apheresis procedures result in mild to moderate adverse reactions, such as hypocalcemia or hypotension, further influencing patient hesitancy. This concern can lead to reluctance, with some patients opting for less invasive or lower-risk alternatives, even if they may not be as effective as apheresis. Addressing these safety concerns through enhanced screening, rigorous infection control, and improved protocols is essential for boosting confidence and adoption. Only by prioritizing safety can the apheresis market overcome this barrier and achieve its growth potential.
Recruitment of Voluntary Non-Remunerated Donors
Apheresis relies heavily on voluntary non-remunerated blood donors, as these individuals provide plasma and platelets that are essential for various life-saving treatments. However, recruiting and retaining these donors presents a significant challenge for the apheresis services market. While many individuals do donate voluntarily, the process itself is both time-consuming and requires considerable commitment. Donors must set aside time for the donation process, which can take over an hour or more, and in some cases, they are required to donate frequently to maintain a steady supply of plasma or platelets. This time investment, coupled with the physical demands of the donation process, can lead to donor fatigue, making it difficult to ensure a consistent flow of willing and eligible donors.
As the demand for plasma and platelet-based therapies continues to rise, especially with the increasing prevalence of chronic diseases and the growing use of plasma-derived therapies, a shortage of donors can become a significant limiting factor. Without a stable supply of high-quality plasma and platelets, the ability to provide apheresis treatments in a timely and effective manner may be compromised, directly impacting the growth of the market. This shortage can also lead to increased competition among healthcare providers to secure donor supplies, further exacerbating the problem.
To address this issue, efforts to incentivize donations—such as providing small rewards, offering recognition, or streamlining the donation process to make it more convenient and less time-consuming—could help alleviate donor fatigue and increase donor retention. Additionally, innovations in blood collection technology, such as automated systems that make the donation process more efficient, may reduce the burden on donors. However, despite these efforts, ensuring a consistent and sufficient supply of voluntary non-remunerated blood donors remains a significant challenge that could restrain the expansion of the apheresis services market. This ongoing issue highlights the need for sustained efforts to improve donor recruitment strategies and the overall donation experience to maintain a reliable supply of plasma and platelets.
Platelet-rich plasma (PRP) therapy has garnered significant attention in recent years, particularly within the fields of orthopedics, dermatology, and sports medicine. The therapy involves using a patient’s own platelets, which are concentrated from their blood, to accelerate healing and tissue regeneration. However, the growing demand for PRP therapy has also led to an increased need for apheresis services, as this technique is often employed to collect platelets from healthy blood donors for PRP treatments. Apheresis allows for the efficient extraction of platelets, which are then used in PRP therapy to treat a variety of conditions such as musculoskeletal injuries, hair loss, and even skin rejuvenation.
In orthopedics, PRP therapy is commonly used to treat tendon injuries, ligament sprains, and osteoarthritis by promoting tissue healing and reducing inflammation. In dermatology, it has gained popularity for its ability to stimulate hair growth in patients with androgenic alopecia (male or female pattern baldness) and improve the appearance of the skin by reducing wrinkles and promoting collagen production. As the clinical applications of PRP therapy expand and its regenerative properties are increasingly recognized, more healthcare providers are incorporating them into treatment regimens. This shift is creating substantial demand for platelet collections, which in turn, is fueling the need for apheresis services.
As PRP therapy continues to grow in popularity across these therapeutic areas, the apheresis services market stands to benefit greatly. The increase in demand for PRP treatments means that apheresis will play a crucial role in providing a sufficient supply of platelets, particularly for treatments involving patients who may not have access to their own platelets or for cases requiring higher volumes of platelets. This trend is expected to create significant growth opportunities within the apheresis services market, especially as the adoption of PRP therapy expands into other areas like regenerative medicine, dentistry, and even cosmetic surgery. Thus, the increasing use of PRP therapy across diverse medical specialties is expected to drive further demand for apheresis services, offering promising prospects for market expansion.
Apheresis for Leukemia and Pediatric Patients
The use of apheresis services in the treatment of leukemia and in pediatric patients represents a rapidly growing opportunity for the U.S. apheresis services market. Apheresis plays a crucial role in the management of leukemia, particularly in removing abnormal cells from the blood, which is essential for patients undergoing treatments like chemotherapy. Additionally, apheresis is commonly utilized in stem cell transplantation, a standard procedure for pediatric leukemia patients.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 110 companies operating in the Apheresis Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
